Thrombocytopenia Market Research Report present a detailed analysis of the market listing Thrombocytopenia Epidemiology, Drug therapies and pipeline for study period from 2016-2027.

Thrombocytopenia Market Size & Share | Market forecast

DelveInsight's 'Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical &amp; forecasted epidemiology as well as the market trends of Thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Thrombocytopenia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
&nbsp;
Geography Covered
&bull; The United States
&bull; EU5 (Germany, France, Italy, Spain and the United Kingdom)
&bull; Japan
&nbsp;
Study Period: 2016-2027
Thrombocytopenia - Disease Understanding and Treatment Algorithm
The DelveInsight Thrombocytopenia market report gives the thorough understanding of the Thrombocytopenia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Thrombocytopenia in the US, Europe, and Japan.
&nbsp;
 Thrombocytopenia Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, prevalent cases by type, prevalent cases by age, prevalent and diagnosed cases of Idiopathic Thrombocytopenic Purpura (ITP), Chemotherapy-Induced Thrombocytopenia (CIT), Heparin-Induced Thrombocytopenia (HIT) and Thrombocytopenia associated with Chronic Liver Disease (CLD)) scenario of Thrombocytopenia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total number of prevalent population of Thrombocytopenia was found to be 817,855, in the year 2016.
&nbsp;
Thrombocytopenia Drug Chapters
This segment of the Thrombocytopenia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
There are several approved therapies, capturing one or the other Thrombocytopenia related causes. N-plate (Amgen) and Promacta (GSK) are the approved drugs for the treatment of patients with chronic immune thrombocytopenic purpura. Octagam (Octapharm USA) is indicated for the treatment of idiopathic thrombocytopenic purpura. Detailed chapter for upcoming therapies like SHP-655 (Shire), Avatrombopag (Dova Pharmaceuticals), BT-595 (Biotest) and Caplacizumab (Ablynx) have been covered in the report.
&nbsp;
Thrombocytopenia Market Outlook
The Thrombocytopenia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Thrombocytopenia in 7MM was found to be USD 1,248 million in 2016.
&nbsp;
Thrombocytopenia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
&nbsp;
 Thrombocytopenia Report Insights
&bull; Patient Population
&bull; Therapeutic Approaches
&bull; Pipeline Analysis
&bull; Market Size and Trends
&bull; Market Opportunities
&bull; Impact of upcoming Therapies
&nbsp;
 Thrombocytopenia Report Key Strengths
&bull; 10 Year Forecast
&bull; 7MM Coverage
&bull; Epidemiology Segmentation
&bull; Drugs Uptake
&bull; Highly Analyzed Market
&bull; Key Cross Competition
&nbsp;
 Thrombocytopenia Report Assessment
&bull; Current Treatment Practices
&bull; Unmet Needs
&bull; Detailed Pipeline Product Profiles
&bull; Market Attractiveness
&bull; Market Drivers and Barriers
&nbsp;
 Key Benefits
&bull; This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Thrombocytopenia market
&bull; Organize sales and marketing efforts by identifying the best opportunities for Thrombocytopenia market
&bull; To understand the future market competition in the Thrombocytopenia market
&nbsp;

1. Key Insights
2. Thrombocytopenia Market Overview at a Glance
2.1. Market Share (%) Distribution of Thrombocytopenia in 2017
2.2. Market Share (%) Distribution of Thrombocytopenia in 2027
3. Disease Background and Overview: Thrombocytopenia
3.1. Introduction
3.2. Causes of Thrombocytopenia
3.3. Pathogenesis
3.4. Pathophysiology
3.5. Etiology
3.6. Symptoms
3.7. Diagnosis and Treatment
3.8. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
3.9. Management of thrombocytopenia
3.10. First Line Therapies
3.11. Second and Third Line Therapies
3.12. Diagnostic and treatment guidelines form thrombotic thrombocytopenic purpura (TTP) 2017 in Japan
3.13. Treatment of Heparin-induced Thrombocytopenia (HIT)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. 7MM Prevalent Population of Thrombocytopenia
4.4. Country Wise-Epidemiology of Thrombocytopenia
4.4.1. United States
4.4.1.1. Prevalent cases of Thrombocytopenia in the United States
4.4.1.2. Prevalent cases of Thrombotic Thrombocytopenic Purpura (TTP) by Type in the United States
4.4.1.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in the United States
4.4.1.4. Prevalent cases of Idiopathic Thrombocytopenic Purpura (ITP) in the United States
4.4.1.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United States
4.4.1.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in the United States
4.4.1.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United States
4.4.1.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United States
4.4.1.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in the United States
4.4.1.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United States
4.4.1.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in the United States
4.4.1.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United States
4.4.2. Germany
4.4.2.1. Prevalent cases of Thrombocytopenia in Germany
4.4.2.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Germany
4.4.2.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Germany
4.4.2.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Germany
4.4.2.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Germany
4.4.2.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Germany
4.4.2.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Germany
4.4.2.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Germany
4.4.2.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Germany
4.4.2.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Germany
4.4.2.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Germany
4.4.2.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Germany
4.4.3. France
4.4.3.1. Prevalent cases of Thrombocytopenia in France
4.4.3.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in France
4.4.3.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in France
4.4.3.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in France
4.4.3.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in France
4.4.3.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in France
4.4.3.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in France
4.4.3.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in France
4.4.3.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in France
4.4.3.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in France
4.4.3.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in France
4.4.3.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in France
4.4.4. Italy
4.4.4.1. Prevalent cases of Thrombocytopenia in Italy
4.4.4.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Italy
4.4.4.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Italy
4.4.4.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Italy
4.4.4.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Italy
4.4.4.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Italy
4.4.4.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Italy
4.4.4.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Italy
4.4.4.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Italy
4.4.4.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Italy
4.4.4.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Italy
4.4.4.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Italy
4.4.5. Spain
4.4.5.1. Prevalent cases of Thrombocytopenia in Spain
4.4.5.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Spain
4.4.5.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Spain
4.4.5.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Spain
4.4.5.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Spain
4.4.5.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Spain
4.4.5.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Spain
4.4.5.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Spain
4.4.5.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Spain
4.4.5.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Spain
4.4.5.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Spain
4.4.5.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Spain
4.4.6. United Kingdom
4.4.6.1. Prevalent cases of Thrombocytopenia in the United Kingdom
4.4.6.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in the United Kingdom
4.4.6.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in the United Kingdom
4.4.6.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in the United Kingdom
4.4.6.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United Kingdom
4.4.6.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in the United Kingdom
4.4.6.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United Kingdom
4.4.6.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in the United Kingdom
4.4.6.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in the United Kingdom
4.4.6.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in the United Kingdom
4.4.6.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in the United Kingdom
4.4.6.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in the United Kingdom
4.4.7. Japan
4.4.7.1. Prevalent cases of Thrombocytopenia in Japan
4.4.7.2. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Type in Japan
4.4.7.3. Prevalent cases of Thrombotic Thrombocytopenic purpura (TTP) by Age in Japan
4.4.7.4. Prevalent cases of Idiopathic Thrombocytopenic purpura (ITP) in Japan
4.4.7.5. Prevalent cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Japan
4.4.7.6. Prevalent cases of Heparin-Induced Thrombocytopenia (HIT) in Japan
4.4.7.7. Prevalent cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Japan
4.4.7.8. Diagnosed Cases of Thrombotic Thrombocytopenia Purpura in Japan
4.4.7.9. Diagnosed cases of Idiopathic Thrombocytopenic purpura (ITP) in Japan
4.4.7.10. Diagnosed cases of Chemotherapy-Induced Thrombocytopenia (CIT) in Japan
4.4.7.11. Diagnosed cases of Heparin-Induced Thrombocytopenia (HIT) in Japan
4.4.7.12. Diagnosed cases of Thrombocytopenia associated with Chronic Liver Disease (CLD) in Japan
5. Unmet needs
6. Marketed Products
7. Octagam: Octapharma USA
7.1. Product Description
7.2. Regulatory Milestones
7.3. Advantages &amp; Disadvantages
7.4. Safety and Efficacy of Octagam
7.5. Side effects of Octagam
7.6. Product Profile
8. Nplate(AMG-531): Amgen
8.1. Product Description
8.2. Regulatory Milestones
8.3. Advantages &amp; Disadvantages
8.4. Safety and Efficacy of Nplate
8.5. Side effects of Nplate
8.6. Product Profile
9. MULPLETA (Lusutrombopag): Shionogi
9.1. Product Description
9.2. Regulatory Milestones
9.3. Safety and Efficacy of Lusutrombopag/MULPLETA
9.4. Side effects of MULPLETA
9.5. Product Profile
10. Privigen: CSL Behring
10.1. Product Description
10.2. Regulatory Milestones
10.3. Advantages &amp; Disadvantages
10.4. Safety and Efficacy of Privigen
10.5. Side effects of Privigen
10.6. Product Profile
11. Rhophylac: CSL Behring
11.1. Product Description
11.2. Regulatory Milestones
11.3. Advantages &amp; Disadvantages
11.4. Safety and Efficacy of Rhophylac
11.5. Side effects of Rhophylac
11.6. Product Profile
12. Emerging Therapies
13. Filed &amp; Phase III Drugs
13.1. Avatrombopag: Dova Pharmaceuticals
13.1.1. Drug Description
13.1.2. Product Profile
13.1.3. Regulatory Milestones
13.1.4. Other Development Activities
13.1.5. Clinical Development
13.1.6. Clinical Trials Information
13.1.7. Safety and efficacy
13.1.8. Advantages and Disadvantages
13.2. Fostamatinib: Rigel Pharmaceuticals
13.2.1. Drug Description
13.2.2. Product Profile
13.2.3. Regulatory Milestones
13.2.4. Clinical Development
13.2.5. Clinical Trials Information
13.2.6. Safety and efficacy
13.2.7. Advantages and Disadvantages
13.3. Caplacizumab: Ablynx
13.3.1.1. Drug Description
13.3.1.2. Product Profile
13.3.1.3. Regulatory Milestones
13.3.1.4. Other Development Activities
13.3.1.5. Clinical Development
13.3.1.6. Clinical Trials Information
13.3.1.7. Safety and efficacy
13.3.1.8. Advantages and Disadvantages
13.4. BT-595: Biotest
13.4.1. Drug Description
13.4.2. Product Profile
13.4.3. Other Development Activities
13.4.4. Clinical Development
13.4.5. Clinical Trials Information
13.4.6. Advantages and Disadvantages
13.5. SHP655: Shire
13.5.1. Drug Description
13.5.2. Product Profile
13.5.3. Regulatory Milestones
13.5.4. Other Development Activities
13.5.5. Clinical Development
13.5.6. Clinical Trials Information
13.5.7. Safety and Efficacy
13.5.8. Advantages and Disadvantages
14. Phase II Drugs
14.1. PRN-1008: Principia Biopharma
14.1.1. Drug Description
14.1.2. Product Profile
14.1.3. Other Development Activities
14.1.4. Clinical Development
14.1.5. Clinical Trials Information
14.2. PRTX-100: Protalex
14.2.1. Drug Description
14.2.2. Product Profile
14.2.3. Regulatory Milestones
14.2.4. Clinical Development
14.2.5. Clinical Trials Information
14.2.6. Safety and Efficacy
14.2.7. Advantages and Disadvantages
14.3. Rozanolixizumab: UCB Biopharma
14.3.1. Drug Description
14.3.2. Product Profile
14.3.3. Other Development Activities
14.3.4. Clinical Development
14.3.5. Clinical Trials Information
14.3.6. Safety and efficacy
14.4. Efgartigimod: Argenx
14.4.1. Drug Description
14.4.2. Product Profile
14.4.3. Other Development Activities
14.4.4. Clinical Development
14.4.5. Clinical Trials Information
14.4.6. Safety and efficacy
14.5. Veltuzumab: Immunomedics
14.5.1. Drug Description
14.5.2. Product Profile
14.5.3. Regulatory Milestones
14.5.4. Other Development Activities
14.5.5. Clinical Development
14.5.6. Clinical Trials Information
14.5.7. Safety and efficacy
15. Thrombocytopenia: Market Analysis
15.1. Key Findings
16. Thrombocytopenia: Total Market Size in 7MM
16.1. Total Market Size of Thrombocytopenia in 7MM
16.2. Type Specific Market Size of Thrombocytopenia in 7MM
17. Market Size of Thrombocytopenia by Country
17.1. United States Market Analysis
17.1.1. Market Size of Thrombocytopenia in the US
17.1.2. Type Specific Market Size of Thrombocytopenia in the US
17.1.3. Market Size of TTP in the US
17.1.4. Therapy Based Market Size of TTP in the US
17.1.5. Therapy Based Market Size of ITP in the US
17.2. Thrombocytopenia: EU5 Market Outlook
17.3. Germany
17.3.1. Market Size of Thrombocytopenia in Germany
17.3.2. Type Specific Market Size of Thrombocytopenia in Germany
17.3.3. Market Size of TTP in Germany
17.3.4. Therapy Based Market Size of TTP in Germany
17.3.5. Therapy Based Market Size of ITP in Germany
17.4. France
17.4.1. Market Size of Thrombocytopenia in France
17.4.2. Type Specific Market Size of Thrombocytopenia in France
17.4.3. Market Size of TTP in France
17.4.4. Therapy Based Market Size of TTP in France
17.4.5. Therapy Based Market Size of ITP in France
17.5. Italy
17.5.1. Market Size of Thrombocytopenia in Italy
17.5.2. Type Specific Market Size of Thrombocytopenia in Italy
17.5.3. Market Size of TTP in Italy
17.5.4. Therapy Based Market Size of TTP in Italy
17.5.5. Therapy Based Market Size of ITP in Italy
17.6. Spain
17.6.1. Market Size of Thrombocytopenia in Spain
17.6.2. Type Specific Market Size of Thrombocytopenia in Spain
17.6.3. Market Size of TTP in Spain
17.6.4. Therapy Based Market Size of TTP in Spain
17.6.5. Therapy Based Market Size of ITP in Spain
17.7. United Kingdom
17.7.1. Market Size of Thrombocytopenia in the UK
17.7.2. Type Specific Market Size of Thrombocytopenia in the UK
17.7.3. Market Size of TTP in the UK
17.7.4. Therapy Based Market Size of TTP in the UK
17.7.5. Therapy Based Market Size of ITP in the UK
17.8. Japan: Market Analysis
17.8.1. Market Size of Thrombocytopenia in Japan
17.8.2. Type Specific Market Size of Thrombocytopenia in Japan
17.8.3. Therapy Based Market Size of ITP in Japan
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
&nbsp;

Thrombocytopenia - Market Insights, Epidemiology and Market Forecast-2027

DelveInsight's 'Thrombocytopenia- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Thrombocytopenia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 